Transarterial approaches to primary and secondary hepatic malignancies

Ali Habib, Kush R Desai, Ryan M Hickey, Bartley Garver Thornburg, Robert J Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. Most patients with hepatic malignancies are not candidates for curative surgical intervention, thereby warranting exploration of alternative means of treatment that preserves quality of life while providing clinical benefit. Herein, the data for intra-arterial chemoinfusion, transarterial chemoembolization, drug-eluting beads, and radioembolization are discussed in the setting of malignancies within the liver; outcome data relating to survival, time-to-progression, time-to-recurrence, and adverse events are presented. Further data regarding different treatment paradigms for hepatocellular carcinoma, metastatic colorectal carcinoma, neuroendocrine tumours, and intrahepatic cholangiocarcinoma are also provided. In light of these and forthcoming data, transarterial therapies seem to offer a viable treatment pathway for select populations of patients.

Original languageEnglish (US)
Pages (from-to)481-489
Number of pages9
JournalNature Reviews Clinical Oncology
Volume12
Issue number8
DOIs
StatePublished - Aug 30 2015

Fingerprint

Liver
Neoplasms
Therapeutics
Neuroendocrine Tumors
Cholangiocarcinoma
Hepatocellular Carcinoma
Colorectal Neoplasms
Quality of Life
Recurrence
Survival
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology

Cite this

@article{4cf7d9ea0d8c4b5eba8568d6bd0afd58,
title = "Transarterial approaches to primary and secondary hepatic malignancies",
abstract = "Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. Most patients with hepatic malignancies are not candidates for curative surgical intervention, thereby warranting exploration of alternative means of treatment that preserves quality of life while providing clinical benefit. Herein, the data for intra-arterial chemoinfusion, transarterial chemoembolization, drug-eluting beads, and radioembolization are discussed in the setting of malignancies within the liver; outcome data relating to survival, time-to-progression, time-to-recurrence, and adverse events are presented. Further data regarding different treatment paradigms for hepatocellular carcinoma, metastatic colorectal carcinoma, neuroendocrine tumours, and intrahepatic cholangiocarcinoma are also provided. In light of these and forthcoming data, transarterial therapies seem to offer a viable treatment pathway for select populations of patients.",
author = "Ali Habib and Desai, {Kush R} and Hickey, {Ryan M} and Thornburg, {Bartley Garver} and Lewandowski, {Robert J} and Riad Salem",
year = "2015",
month = "8",
day = "30",
doi = "10.1038/nrclinonc.2015.78",
language = "English (US)",
volume = "12",
pages = "481--489",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "8",

}

Transarterial approaches to primary and secondary hepatic malignancies. / Habib, Ali; Desai, Kush R; Hickey, Ryan M; Thornburg, Bartley Garver; Lewandowski, Robert J; Salem, Riad.

In: Nature Reviews Clinical Oncology, Vol. 12, No. 8, 30.08.2015, p. 481-489.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Transarterial approaches to primary and secondary hepatic malignancies

AU - Habib, Ali

AU - Desai, Kush R

AU - Hickey, Ryan M

AU - Thornburg, Bartley Garver

AU - Lewandowski, Robert J

AU - Salem, Riad

PY - 2015/8/30

Y1 - 2015/8/30

N2 - Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. Most patients with hepatic malignancies are not candidates for curative surgical intervention, thereby warranting exploration of alternative means of treatment that preserves quality of life while providing clinical benefit. Herein, the data for intra-arterial chemoinfusion, transarterial chemoembolization, drug-eluting beads, and radioembolization are discussed in the setting of malignancies within the liver; outcome data relating to survival, time-to-progression, time-to-recurrence, and adverse events are presented. Further data regarding different treatment paradigms for hepatocellular carcinoma, metastatic colorectal carcinoma, neuroendocrine tumours, and intrahepatic cholangiocarcinoma are also provided. In light of these and forthcoming data, transarterial therapies seem to offer a viable treatment pathway for select populations of patients.

AB - Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. Most patients with hepatic malignancies are not candidates for curative surgical intervention, thereby warranting exploration of alternative means of treatment that preserves quality of life while providing clinical benefit. Herein, the data for intra-arterial chemoinfusion, transarterial chemoembolization, drug-eluting beads, and radioembolization are discussed in the setting of malignancies within the liver; outcome data relating to survival, time-to-progression, time-to-recurrence, and adverse events are presented. Further data regarding different treatment paradigms for hepatocellular carcinoma, metastatic colorectal carcinoma, neuroendocrine tumours, and intrahepatic cholangiocarcinoma are also provided. In light of these and forthcoming data, transarterial therapies seem to offer a viable treatment pathway for select populations of patients.

UR - http://www.scopus.com/inward/record.url?scp=84938212718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938212718&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2015.78

DO - 10.1038/nrclinonc.2015.78

M3 - Review article

C2 - 25985939

AN - SCOPUS:84938212718

VL - 12

SP - 481

EP - 489

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 8

ER -